NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Forecast & News

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, October, 31st. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.30. The biotechnology company had revenue of $131.17 million for the quarter, compared to the consensus estimate of $97.10 million. Ironwood Pharmaceuticals had a negative net margin of 9.67% and a negative return on equity of 15.83%. Ironwood Pharmaceuticals's quarterly revenue was up 99.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.27) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Ironwood Pharmaceuticals.

10 brokerages have issued 12 month target prices for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $14.67 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

News coverage about IRWD stock has trended somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ironwood Pharmaceuticals earned a news sentiment score of 0.6 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 26,970,000 shares, an increase of 6.0% from the November 14th total of 25,450,000 shares. Based on an average daily volume of 1,657,700 shares, the days-to-cover ratio is currently 16.3 days. Approximately 17.7% of the shares of the stock are sold short. View Ironwood Pharmaceuticals' Current Options Chain.

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.72%), Peregrine Capital Management LLC (0.81%), Millennium Management LLC (0.66%), Colony Group LLC (0.33%), Squarepoint Ops LLC (0.25%) and Chicago Equity Partners LLC (0.25%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, SG Americas Securities LLC, First Trust Advisors LP, Broderick Brian C and Chicago Equity Partners LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Colony Group LLC, Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Peregrine Capital Management LLC, First Quadrant L P CA and Redwood Investment Management LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $12.79.

Ironwood Pharmaceuticals has a market capitalization of $2.01 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]